We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current RNAC market cap is 469.41M. The company's latest EPS is USD -8.6449 and P/E is -2.14.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 5.25M | 6.55M | 8.27M | 5.84M | 33.45M |
| Operating Income | -18.64M | -13.07M | -36.33M | -13.35M | 13.46M |
| Net Income | -11.39M | -9M | -177.66M | -56.82M | 13.84M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.68M | 16.6M | 85.08M | 110.78M | 26M |
| Operating Income | -52.46M | -56.82M | -4.6M | 14.54M | -86.42M |
| Net Income | -55.35M | -68.88M | -25.69M | 35.38M | -219.71M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 139.51M | 106.03M | 305.05M | 325.21M | 347.74M |
| Total Liabilities | 74.06M | 45.71M | 444.68M | 442.01M | 449.2M |
| Total Equity | 65.45M | 60.33M | -440.18M | -116.8M | -101.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 99.57M | 165.44M | 159.88M | 165.89M | 305.05M |
| Total Liabilities | 91.17M | 183.44M | 137.36M | 72.06M | 444.68M |
| Total Equity | 8.4M | -18.01M | 22.52M | 93.83M | -440.18M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.66M | -27.88M | -51.16M | -15.92M | -30.36M |
| Investing | 28.11M | 28.11M | 34.61M | -602k | -2.19M |
| Financing | -2.44M | -27.23M | -13.15M | 43.03M | 43.15M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -51.44M | 34.88M | -60.38M | -31.63M | -51.16M |
| Investing | 229k | -741k | -17.14M | -15M | 34.61M |
| Financing | 105.04M | 14.43M | 52.9M | 39.22M | -13.15M |
| Market Cap | 469.41M |
| Price to Earnings Ratio | -2.14 |
| Price to Sales Ratio | 18.05 |
| Price to Cash Ratio | 6.1 |
| Price to Book Ratio | -3.36 |
| Dividend Yield | - |
| Shares Outstanding | 25.41M |
| Average Volume (1 week) | 270.86k |
| Average Volume (1 Month) | 165.99k |
| 52 Week Change | -16.24% |
| 52 Week High | 41.87 |
| 52 Week Low | 11.665 |
| Spread (Intraday) | 4.37 (20.7%) |
| Company Name | Cartesian Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.selectabio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
